Rodon, Jordi
Soria, Jean-Charles
Berger, Raanan
Miller, Wilson H.
Rubin, Eitan http://orcid.org/0000-0002-7807-4005
Kugel, Aleksandra
Tsimberidou, Apostolia
Saintigny, Pierre
Ackerstein, Aliza
Braña, Irene
Loriot, Yohann
Afshar, Mohammad
Miller, Vincent
Wunder, Fanny
Bresson, Catherine
Martini, Jean-François
Raynaud, Jacques
Mendelsohn, John
Batist, Gerald
Onn, Amir
Tabernero, Josep http://orcid.org/0000-0002-2495-8139
Schilsky, Richard L.
Lazar, Vladimir
Lee, J. Jack http://orcid.org/0000-0001-5469-9214
Kurzrock, Razelle http://orcid.org/0000-0003-4110-1214
Article History
Received: 8 November 2018
Accepted: 14 March 2019
First Online: 22 April 2019
Competing interests
: J.Rodon reports non-financial support and reasonable reimbursement for travel from the <i>European Journal of Cancer</i>, Vall d’Hebron Institut of Oncology, the Chinese University of Hong Kong, SOLTI, Elsevier, GlaxoSmithKline; receives consulting and travel fees from Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceutical/Klus Pharma, Spectrum Pharmaceuticals, Pfizer, Roche Pharmaceuticals and Ellipses Pharma (including serving on the scientific advisory board from 2015 to present); receives research funding from Bayer and Novartis; and serves as investigator in clinical trials with Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAtla, Pfizer, GenMab, CytomX, Kelun Pharmaceutical/Klus Pharma, Takeda-Millenium, GlaxoSmithKline and Ipsen. J.-C.S. received consultancy fees from AstraZeneca, Roche, Sanofi, Servier, Pierre Fabre and is a full-time employee of Medimmune/AstraZeneca since September 2017. W.H.M. receives speaking and/or consulting fees from BMS, Merck, Roche, Novartis and Amgen. E.R. received consultant fees from Teva, Carmentix and Hinoman, is receiving consultant fees from Equinom and has ownership interest in Carmentix. A.O. receives consulting fees from Roche Israel, MSD Israel, Boehringer Ingelheim and AstraZeneca. A.T. received consultant fees from Roche and receives research funding from EMD Serono, Baxter, Foundation Medicine, ONYX and Bayer. P.S. collaborates in research with Roche, AstraZeneca, BMS and Novartis. I.B. receives consultant fees from Orion Pharma, receives speaking fees from BMS, AstraZeneca and Merck Serono, and is principal investigator and receives funding for clinical trials from AstraZeneca, BMS, Celgene, Gliknik, GSK, Janssen, KURA, MSD, Novartis, Orion Pharma and Pfizer. Y.L. collaborates in research with Merck, Roche, AstraZeneca, Sanofi, Pfizer, Janssen, Astellas and BMS. M.A. is an employee and shareholder of Ariana Pharmaceuticals. V.M. is an employee (salary and equity) of Foundation Medicine. J.-F.M. is a full-time employee and stockholder of Pfizer. G.B. collaborates in formal clinical trial contracts, investigator initiated trials (IITs) and in joint grants funded by the Canadian and Québec governments with Roche, Merck, Novartis, AstraZeneca, Bayer, Esperas, Aurka, Caprion and MRM-P. J.T. declares a scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Genmab A/S, Halozyme, Imugene, Inflection Biosciences, Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics. R.K. has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta and OmniSeq, as well as consultant fees from LOXO, X-Biotech, Actuate Therapeutics, Roche and NeoMed. She serves as an advisor to Soluventis. She receives speaker fees from Roche and also has equity in IDbyDNA, CureMatch and Soluventis. F.W., C.B. and V.L. are full-time employees of WIN Association–WIN Consortium. WIN Association–WIN Consortium is the owner of the patent family entitled ‘Method for predicting efficacy of drugs in a patient’ (WINTHER). The inventors are V.L., J.-C.S., Michel Ducreux and Thomas Tursz.